

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, 5/00	A1	(11) International Publication Number: WO 97/37009 (43) International Publication Date: 9 October 1997 (09.10.97)
(21) International Application Number: PCT/US97/04736 (22) International Filing Date: 24 March 1997 (24.03.97) (30) Priority Data: 08/626,054 1 April 1996 (01.04.96) US (71) Applicant: UNIVERSITY OF MASSACHUSETTS, A PUBLIC INSTITUTION OF HIGHER EDUCATION OF THE COMMONWEALTH OF MASSACHUSETTS, represented by ITS AMHERST CAMPUS [US/US]; Office of Vice Chancellor for Research at Amherst, Amherst, MA 01002 (US). (72) Inventors: STICE, Steven, L.; 468 Amherst Road, Belchertown, MA 01007 (US). GOLUEKE, Paul, J.; 8 Diane Drive, Belchertown, MA 01007 (US). (74) Agents: TESKIN, Robin, L. et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CULTURED INNER CELL MASS CELL LINES DERIVED FROM UNGULATE EMBRYOS (57) Abstract Novel cultured inner cell mass (CICM) cells, and cell lines, derived from ungulates, in particular, pigs and cows, and methods for their preparation are provided. The subject CICMs possess similar morphology and express cell markers identically or substantially similarly to ICMs of undifferentiated developing embryos for prolonged culturing periods. Heterologous DNAs may be introduced into the subject CICM cells and cell lines to produce transgenic cells useful for the production of transgenic embryos, fetuses and/or offspring, e.g., by nuclear transfer procedures.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

CULTURED INNER CELL MASS CELL LINES
DERIVED FROM UNGULATE EMBRYOS

5 Field of the Invention

Novel cultured inner cell mass (CICM) cells, cell lines, and methods for their preparation are provided. The subject CICMs possess similar morphology and express cell markers identically or highly similarly to ICMs of developing embryos for prolonged culturing periods. These CICMs are produced by novel culturing techniques and/or by introduction of a regulatable differentiation inhibiting gene (DI). The subject CICM cell lines are used to produce differentiated cells, tissues, organs and/or whole animals, preferably ungulates, desirably those which have been genetically modified to contain within their genome a desired heterologous DNA or which have been selected to contain genetically desirable traits. This is accomplished by in vitro culture techniques or by producing chimeric or nuclear transfer embryos, fetuses and/or offspring. Moreover, the CICM cells can also be used for cloning (nuclear transfer procedures) to produce genetically identical embryos, fetuses and/or offspring.

25 Background of the Invention

Methods for deriving embryonic stem (ES) cell lines in vitro from early preimplantation mouse embryos are well known. (See, e.g., Evans et al., Nature, 29:154-156 (1981); Martin, Proc. Natl. Acad. Sci., USA, 78:7634-7638 (1981)). ES cells can be passaged in an undifferentiated state, provided that a feeder layer of fibroblast cells (Evans et al., Id.) or a differentiation inhibiting source (Smith et al., Dev. Biol., 121:1-9 (1987)) is present.

ES cells have been previously reported to possess numerous applications. For example, it has been reported that ES cells can be used as an in vitro model for differentiation, especially for the study of genes which are

-2-

involved in the regulation of early development. Mouse ES cells can give rise to germline chimeras when introduced into preimplantation mouse embryos, thus demonstrating their pluripotency (Bradley et al., Nature, 309:255-256 (1984)).

5 In view of their ability to transfer their genome to the next generation, ES cells have potential utility for germline manipulation of livestock animals by using ES cells with or without a desired genetic modification. Moreover, in the case of livestock animals, e.g., ungulates, nuclei
10 from like preimplantation livestock embryos support the development of enucleated oocytes to term (Smith et al., Biol. Reprod., 40:1027-1035 (1989); and Keefer et al., Biol. Reprod., 50:935-939 (1994)). This is in contrast to nuclei from mouse embryos which beyond the eight-cell stage after
15 transfer reportedly do not support the development of enucleated oocytes (Cheong et al., Biol. Reprod. 48:958 (1993)). Therefore, ES cells from livestock animals are highly desirable because they may provide a potential source of totipotent donor nuclei, genetically manipulated or
20 otherwise, for nuclear transfer procedures.

Many research groups have reported the isolation of purportedly pluripotent embryonic cell lines. For example, Notarianni et al., J. Reprod. Fert. Suppl., 43:255-260 (1991), report the establishment of purportedly stable,
25 pluripotent cell lines from pig and sheep blastocysts which exhibit some morphological and growth characteristics similar to that of cells in primary cultures of inner cell masses isolated immunosurgically from sheep blastocysts. (Id.) Also, Notarianni et al., J. Reprod. Fert. Suppl.,
30 41:51-56 (1990) discloses maintenance and differentiation in culture of putative pluripotential embryonic cell lines from pig blastocysts. Further, Gerfen et al., Anim. Biotech., 6(1):1-14 (1995) disclose the isolation of embryonic cell lines from porcine blastocysts. These cells are stably
35 maintained in mouse embryonic fibroblast feeder layers without the use of conditioned medium. These cells report-

-3-

edly differentiate into several different cell types during culture (Gerfen et al., Id.).

Further, Saito et al., Roux's Arch. Dev. Biol., 201:134-141 (1992) report bovine embryonic stem cell-like cell lines cultured which survived passages for three, but were lost after the fourth passage. Still further, Handyside et al., Roux's Arch. Dev. Biol., 196:185-190 (1987) disclose culturing of immunosurgically isolated inner cell masses of sheep embryos under conditions which allow for the isolation of mouse ES cell lines derived from mouse ICMS. Handyside et al. (1987) (Id.), report that under such conditions, the sheep ICMS attach, spread, and develop areas of both ES cell-like and endoderm-like cells, but that after prolonged culture only endoderm-like cells are evident. (Id.)

Recently, Cherny et al., Theriogenology, 41:175 (1994) reported purportedly pluripotent bovine primordial germ cell-derived cell lines maintained in long-term culture. These cells, after approximately seven days in culture, produce ES-like colonies which stain positive for alkaline phosphatase (AP), exhibit the ability to form embryoid bodies, and spontaneously differentiate into at least two different cell types. These cells also reportedly express mRNA for the transcription factors OCT4, OCT6 and HES1, a pattern of homeobox genes which is believed to be expressed by ES cells exclusively.

Also recently, Campbell et al., Theriogenology, 43:181 (1995) in an abstract report the production of live lambs following nuclear transfer of cultured embryonic disc (ED) cells from day nine ovine embryos cultured under conditions which promote the isolation of ES cell lines in the mouse. The authors conclude based on their results that ED cells from day nine ovine embryos are totipotent by nuclear transfer and that totipotency is maintained in culture for up to three passages.

-4-

Even more recently, Campbell et al, Nature, 380:64-68 (1996) reported cloning of sheep by nucleic transfer from a cultured cell line. The cells used are unlike the CICM's of the present invention. Unlike the subject CICM cells, the cells of Campbell et al formed a monolayer in tissue culture. The authors refer to these cells as being "flattened" or as exhibiting an "epithelial" appearance. By contrast, the CICM cells of the present invention can be continually maintained in a multilayer colony or portions of the colony when grown in an undifferentiated state. Also, the cells of Campbell et al are cytokeratin and are laminin A/C positive. By contrast, the CICM cells of the present invention are cytokeratin negative.

Moreover, there is no suggestion that the cells of Campbell et al are undifferentiated. Rather, the reference only indicates that these cells are useful in nucleic transfer procedures. Also, these cells are not cultured under conditions wherein they maintain constant contact with a fibroblast feeder layer. Rather, the cultured cells (of Campbell et al (1996) apparently push the fibroblasts to the side in culture and grow on top of the culture dish.

Van Stekelenburg-Hamers et al., Mol. Reprod. Dev., 40:444-454 (1995), reported the isolation and characterization of purportedly permanent cell lines from inner cell mass cells of bovine blastocysts. The authors isolated and cultured ICMs from 8 or 9 day bovine blastocysts under different conditions to determine which feeder cells and culture media are most efficient in supporting the attachment and outgrowth of bovine ICM cells. They concluded based on their results that the attachment and outgrowth of cultured ICM cells is enhanced by the use of STO (mouse fibroblast) feeder cells (instead of bovine uterus epithelial cells) and by the use of charcoal-stripped serum (rather than normal serum) to supplement the culture medium. Van Stekelenburg et al report, however, that their cell lines

-5-

resembled epithelial cells more than pluripotent ICM cells.
(Id.)

Still further, Smith et al., WO 94/24274, published October 27, 1994, Evans et al, WO 90/03432, published April 5, 1990 and Wheeler et al, WO 94/26889 published November 24, 1994 report the isolation, selection and propagation of animal stem cells which purportedly may be used to obtain transgenic animals. Also, Evans et al., WO 90/03432, published on April 5, 1990, report the derivation of purportedly pluripotent embryonic stem cells derived from porcine and bovine species which assertedly are useful for the production of transgenic animals. Further, Wheeler et al., WO 94/26884, published November 24, 1994, disclose embryonic stem cells which are assertedly useful for the manufacture of chimeric and transgenic ungulates. Thus, based on the foregoing, it is evident that many groups have attempted to produce ES cell lines, e.g., because of their potential application in the production of cloned or transgenic embryos and in nuclear transplantation.

The use of ungulate ICM cells for nuclear transplantation has also been reported. For example, Collas et al., Mol. Reprod. Dev., 38:264-267 (1994) disclose nuclear transplantation of bovine ICMs by microinjection of the lysed donor cells into enucleated mature oocytes. The reference discloses culturing of embryos in vitro for seven days to produce fifteen blastocysts which, upon transferral into bovine recipients, resulted in four pregnancies and two births. Also, Keefer et al., Biol. Reprod., 50:935-939 (1994), disclose the use of bovine ICM cells as donor nuclei in nuclear transfer procedures, to produce blastocysts which, upon transplantation into bovine recipients, resulted in several live offspring. Further, Sims et al., Proc. Natl. Acad. Sci., USA, 90:6143-6147 (1993), disclose the production of calves by transfer of nuclei from short-term in vitro cultured bovine ICM cells into enucleated mature oocytes.

-6-

Also, the production of live lambs following nuclear transfer of short-term cultured embryonic disc cells (up to three passages) has been reported (Campbell et al., Theriogenology, 43:181 (1995)). Still further, the use of bovine pluripotent embryonic cells in nuclear transfer and the production of chimeric fetuses has also been reported (Stice et al., Theriogenology, 41:301 (1994)).

However, notwithstanding what has been previously reported in the literature, there still exists a significant need for cultured ICM cells and cell lines which possess improved properties, e.g., which possess morphological properties and express cell markers identically or substantially similar to ICM cells of developing embryos, in particular ungulate embryos. There further exists a significant need in the art for methods of producing such improved cultured ICM cells and cell lines.

Objects of the Invention

It is therefore an object of the invention to provide novel and improved cultured inner cell mass (ICM) cells and cell lines.

It is a more specific object of the invention to provide novel and improved cultured ICM cells and cell lines which exhibit morphological characteristics and express cell markers identically or substantially similarly to that of the ICM of developing embryos.

It is an even more specific object of the invention to provide novel and improved ungulate cultured ICM cells and cell lines which exhibit morphological characteristics and express cell markers identically or substantially similarly to that of ICM of developing ungulate embryos.

It is another specific object of the invention to provide improved cultured ICM cells and cell lines, preferably derived from ungulates, which exhibit morphological characteristics and which express cell markers identically

-7-

or substantially similarly to ICM of developing ungulate embryos, for prolonged culturing periods.

It is another specific object of the invention to provide novel methods for the isolation and/or production of such improved ungulate cultured ICM cells and cell lines.

It is a more specific object of the invention to provide novel methods for the isolation and/or production of cultured ungulate ICM cells or cell lines which exhibit morphological characteristics and which express cell markers identically or substantially similarly to the ICM of developing ungulate embryos, preferably for long periods in culture.

It is a specific object of the invention to provide a novel method for culturing and selecting ICM cells or cell lines which exhibit morphological characteristics and express cell markers identically or substantially similarly to ICMs of developing ungulate embryos, which method comprises:

(i) obtaining an ICM of a blastocyst or ICM progenitor cells from preblastocyst stage embryos by mechanical and/or enzymatic means;

(ii) culturing said ICM on a feeder layer culture, preferably fibroblasts; and

(iii) identifying from among said cultured cells those cells which exhibit the following properties;

(a) small cytoplasmic/nuclear volume ratio;

(b) cytoplasmic vesicles; and

(c) small individual cells;

(iv) separating cells having such properties from the remaining cultured cells; and

(v) passaging said separated cells onto a feeder layer, preferably fibroblasts, under conditions such that the separated cells are in direct physical contact with the feeder layer.

It is a more specific object of the invention to produce improved cultured ICMs by the following steps:

-8-

(i) obtaining an ICM of blastocyst stage embryos, preferably ungulates, by suitable mechanical and/or enzymatic means;

5 (ii) culturing said obtained ICM onto a confluent, preferably thick, feeder cell monolayer preferably comprised of fibroblast cells;

10 (iii) culturing said ICM under conditions which result in a multilayer cell colony which includes a substantially inner population of flattened epithelial-like cells and a second multilayered population of cells which substantially surrounds said inner epithelial-like cells and includes relatively small cells having cytoplasmic vesicles, and small cytoplasmic/nuclear volume ratios;

15 (iv) separating said second multilayered population of cells which are substantially comprised on the perimeter of the multilayer cell colony by suitable non-degradative means, i.e., mechanical and/or enzymatic means; and

20 (v) passaging said separated cells onto a new feeder layer preferably comprised of fibroblasts under conditions such that the separated cells are in direct physical contact with the feeder layer.

It is another object of the invention to provide cultured ICMs which exhibit morphological characteristics and which express cell markers identically or substantially similar to that of ICMs of developing ungulate embryos by a method comprising:

25

(i) obtaining ungulate ICM cells or an established cultured ungulate ICM cell line;

30 (ii) introducing into the nucleus of said ICM cells or said established cultured ICM cell line one or more genes which inhibit differentiation, (DI genes) which DI gene or DI genes are preferably expressed under the control of an inducible promoter;

35 (iii) culturing the resultant transgenic ICM cells or cultured ICM cell line on a feeder layer, preferably a confluent fibroblast layer, under conditions which provide

-9-

for the expression of said differentiation inhibiting gene or genes.

It is also an object of the invention to use ICM cells or cell lines which express one or more DI genes in the
5 above-described culturing method.

It is another specific object of the invention to use the subject improved cultured ICMs which exhibit morphological characteristics and express cell markers identically or substantially similarly to ICMs of developing ungulate
10 embryos for any usage wherein ICMs or cultured ICMs have applicability. Such usages include, e.g., the production of differentiated cells, tissues, organs and/or whole animals by *in vitro* cell culture techniques or the production of chimeric or nuclear transfer embryos which may or may not be
15 transgenic.

It is a specific object of the invention to provide cultured ICM cells which may be used in cloning (nuclear transfer procedures) to produce genetically identical ungulate embryos, fetuses and/or offspring or to produce chimeric ungulate embryos, fetuses or offspring.
20

It is another specific object of the invention to use the subject cultured ICMs or cell lines derived therefrom for integration of desired heterologous DNAs, and to use the resultant transgenic cultured ICMs to produce transgenic
25 ungulate embryos, fetuses, and/or offspring or to produce transgenic chimeric ungulate embryos, and/or offspring.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a photograph of cultured C1CM cells grown
30 without feeder layer contact. Embryoid bodies may be observed.

Figure 2 is a photograph of cytokeratin positive cultured C1CM cells.

Figure 3 is a photograph of C1CM cells on a fibroblast
35 feeder layer. Multiple layer colonies are visible after only 2 days of culturing.

-10-

Figures 4 and 5 are photographs showing AP positive and cytokeratin negative CICM cell colonies.

Figures 6 and 7 are photographs showing epithelial-like cells which are obtained during culturing of CICM cells.

5 Those cells are AP negative and cytokeratin positive.

Figure 8 is a photograph of CICM cell colonies. This photo shows that multilayer colonies are beginning to flatten into epithelial-like cell sheets. The cells in the middle of the colony are AP negative and exhibit a flattened epithelial-like appearance. By contrast, cells in the perimeter are smaller, exhibit a multilayered morphology and possess cytoplasmic vesicles.

Figure 9 is a photograph showing cultured pig CICM cells expressing a beta-galactosidase DNA construct five days after microinjection.

DETAILED DESCRIPTION OF THE INVENTION

Prior to discussing the invention in more detail, the following definitions are provided.

20 Inner cell mass cells (ICM cells): This is one of two distinct cell types which are produced during early embryonic development, i.e., the blastocyst and eventually forms part of the feeder. These cells have known application in nuclear transfer techniques, and for producing chimeric and cloned offspring.

Trophectoderm (TE cells): This refers to the second of two distinct cell types which are produced during early embryonic development, i.e., the blastocyst stage and eventually forms part of the placenta.

30 ICM progenitor cells: These are cells comprised in pre-blastocyst stage embryos which develop into ICM cells.

Cultured inner cell mass cells: This refers to inner cell mass cells which have been cultured in vitro for a prolonged period of time.

35 Cultured inner cell mass (CICM or cultured ICM) are cells which exhibit morphological characteristics and which

-11-

express cell markers identically or substantially similarly to inner cell mass cells of developing embryos: In the present invention, this will refer to cultured ICM cells which exhibit a morphology identical or highly similar to the ICM of developing embryos; e.g., ungulate embryos. In general, such cells will grow as small multilayer colonies; however, some cells may differentiate if the colony size exceeds approximately 50 to 100 cells.

CICMs which express cell markers identically to ICMS of developing ungulate embryos refers to CICM cells which express or do not express cell markers in a manner which is characteristic of undifferentiated ICMS of developing ungulate embryos. Suitable cell markers which may be used to identify suitable CICMs include by way of example cytokeratin 8 and cytokeratin 18, enzymes such as alkaline phosphatase, and other cell markers expressed in ICMS such as rex-1, 1 amin ac, and oct4. Ideally, the levels of expression (if any) of such cell markers will be the same as in undifferentiated ICMS obtained from ungulate embryos.

CICMs which express cell markers substantially similarly to ICMS of developing ungulate embryos refers to CICMs which express a majority of cell markers which are characteristic of undifferentiated developing ungulate ICM embryos, e.g., cytokeratin 8 and cytokeratin 18 and enzymes such as alkaline phosphatase, and other cell markers such as rex-1 ac and oct4. Substantially similar refers to the fact that the amount of expression of some cell markers may vary, and some cell markers may be expressed differently in the subject CICMs than in undifferentiated ICMS of ungulate embryos provided that this does not adversely affect the ability of the resultant CICMs to be cultured and maintained according to the invention.

In general, CICM cells which express cell markers identically or substantially similarly to ICMS of developing ungulate embryos will not express cytokeratin 18, and will

-12-

express alkaline phosphatase. Methods for detecting the expression of such cell markers and others are known in the art (some of which are referenced *infra*) and include by way of example immunodetection methods. For example, such methods detect the expression or lack of expression of a particular cellular marker based on reactivity of cells with a suitable immunoprobe, e.g., a labeled antibody which provides for specific detection.

However, as discussed *infra*, there may be species differences in cell marker expression. (For example, whereas CICMs obtained from pigs are AP positive, CICMs obtained from cows are predominantly AP negative.) Moreover, the cultured ICMs of the present invention may also contain genes which are not normally contained in ICs, e.g., genes which encode for a desired product and/or one or more genes which inhibit differentiation.

Differentiation inhibiting gene: In the present invention this will typically refer to any nucleic acid sequence which inhibits the differentiation of ICs. This includes by way of example tsA58 as well as other genes encoding other T antigens and oncogene products, cytokines and transcription factors, e.g., OCT3, LIF and LIF receptor. Such differentiation inhibiting genes are known in the art and are described in WO 91/13150; Okamoto et al., Cell, 60:461 (1990); Rosner et al., Nature, 345:686 (1990); and Smith et al., Nature, 336:688 (1988), all of which are incorporated by reference in their entirety herein. Other suitable genes include REX-1 (Rodgers et al, Develop. 113:815-824 (1991)), and FGF-5 (Herbert et al, Develop. 112:407-415 (1991).)

Inducible or regulatable promoter: This refers to any promoter which, when operably linked to a desired structural gene, e.g., a differentiation inhibiting gene, is "turned on", i.e., promotes transcription, under specific conditions. Typically, this requires the presence or absence of one or more substituents in the culture medium, e.g., metal

-13-

ions, or other specific culturing conditions, e.g., particular temperature conditions, etc. Examples of well known inducible or regulatable promoters include by way of example response elements such as tetracycline (WO 94/29442), interferon (Kimura et al., Cell, 44:261 (1986)), steroid and metallothionein promoters (Yarranton, G.T., Curr. Opin. Biotech., 3:506 (1992)), temperature inducible promoters, etc. These references are incorporated by reference in their entirety.

10 Feeder cells: This refers to any cells which can be used to obtain and/or propagate undifferentiated cultured ICM cell lines. Preferably, such feeder cells will be fibroblasts, and more preferably murine embryonic fibroblasts, e.g., from 12-16 day old murine fetuses. Other
15 suitable feeder cells include, e.g., fibroblast and uterine epithelial cells from ungulates, chicken fibroblasts, rat fibroblast, STO and SI-m220 feeder cell lines, and BRL cells.

Cultured multilayer ICM colony: This refers to a
20 growing multilayer colony of cultured ICMs on the feeder layer which exhibits a multilayer structure possessing two different, distinct cell populations. The first cell population substantially constitutes the perimeter of the multilayer cell colony and is multilayered. The cells therein
25 include cells which are relatively small, possess cytoplasmic vesicles, and which stain strongly positive for AP activity. The other cell population is substantially comprised in the middle of the cell colony and substantially consists of a flattened epithelial-like population of cells
30 which exhibit little or no AP activity.

 As discussed, the present invention is generally directed to cultured ICM cells and cell lines which exhibit improved properties in relation to previously reported cultured ICMs. In particular, these cultured ICMs and cells
35 exhibit morphological characteristics and express cell

-14-

markers identically or substantially similarly to the ICMS of developing embryos.

The present invention provides cultured ICMS which possess a novel combination of properties which are identical or substantially similar to ICMS of developing ungulate embryos, i.e., they possess the above-defined multilayer cell colony morphology, and express cell markers identically or substantially similarly to ICMS of developing ungulate embryos, e.g., they do not express cytokeratin 18 and may or may not express alkaline phosphatase (depending on particular species of origin.)

Both the alkaline phosphatase marker and cytokeratin 18 marker have been used independently by previous researchers to determine whether cultured cells are putatively similar to developing ungulate ICMS (Piedrahita et al., Theriogenology, 34:879 (1990), Wheeler et al., Reprod. Fert. Dev., 6:563 (1994) and Talbot et al., Mol. Reprod. Dev., 36:139 (1993)). Thus, the expression of these cell markers by the ICMS produced herein provides strong evidence that the subject culturing techniques may be used to obtain ICMS which are identical or substantially similar to ICMS found in developing ungulate embryos.

This is in contrast to previously disclosed cultured ICMS, such as the cultured pig ICMS of Talbot et al (Id.) which, after culturing for only two weeks in vitro, differentiated and lost AP activity. The subject cultured ICMS are also different from the cultured bovine ICM cells of Sims et al. (Id.), which were cultured for short periods of time but which were disaggregated and grown as individual cells in a cell suspension system. The subject cultured ICMS are further different from ES-like cells which have been previously described in the literature which grow as an epithelial monolayer and which are AP negative and cytokeratin positive. Further, the subject cultured ICMS are different from those of Wheeler, Reprod. Fert. Dev., 6:563 (1994) and WO 94/26884 which, while growing in multilayer

-15-

colonies and being cytokeratin negative (similar to CICM cell lines of the present invention) are feeder layer independent.

Thus, the subject invention provides novel CICM cells
5 and cell lines which, given their morphological and cell marker characteristics, should be well suited for chimera and nuclear transfer studies to produce differentiated cells, fetuses and offspring. In general, the subject novel CICM cell lines are produced by either of the following two
10 methods.

The first method comprises obtaining ICMs of blastocyst or ICM progenitor cells from preblastocyst stage embryos, preferably those derived from ungulates. Ungulates include many important livestock animals, e.g., swine, cattle,
15 sheep, horses and goats. Therefore, cultured ungulate cells potentially suitable for the production of ungulate animals are highly desirable. Also, ungulates afford significant advantages over other species known to be useful for production of cultured ICMs and transgenic or cloned animals,
20 e.g., rodents, because they are immunologically and physiologically more similar to humans.

Ungulate embryos of blastocyst or preblastocyst stage may be obtained by well known methods. For example, blastocyst or preblastocyst embryos may be surgically collected
25 from the reproductive tract of ungulates, e.g., pigs or cows, post mortem during surgical laparotomy, or non-surgically. Generally these embryos will range in age from 2 to 15 days and preferably 8 days. After collection, the ICMs of the blastocyst or preblastocyst stage ungulate embryos
30 will either be partially separated (e.g. ICM separated from the trophoblast cells) or left intact. If partial separation is effected, it is typically effected by suitable mechanical and/or enzymatic methods, e.g., by use of a culturing glass needle and/or by incubation with trypsin or
35 pronase.

-16-

The partially separated or intact ICMs of the blastocyst which contains the ICM and at least a portion of the trophectoderm or ICM progenitor cells derived from preblastocyst stage embryos are then introduced onto a suitable feeder cell layer culture medium. All cells derived from preblastocyst stage embryos are introduced onto a suitable feeder layer. As discussed *supra*, the feeder cell layer will comprise any cell layer which allows for the selection and/or propagation of undifferentiated ICMs. Preferably, the feeder cell layer will comprise fibroblasts, and more preferably those derived from primary cultures of embryonic murine fibroblasts. However, it is expected that fibroblast cell lines or other types of fibroblasts may be substituted therefor.

It has been found by the present inventors that the morphological characteristics of the feeder layer is an important factor in obtaining and propagating undifferentiated CICM cell lines in culture. More particularly, it has been found that the culture plate used for culturing the ICMs should preferably comprise a thick confluent monolayer of feeder cells, more preferably a thick confluent monolayer of murine fibroblast cells.

As discussed in greater detail in the Examples, the feeder layer is preferably obtained from primary cultures of embryonic fibroblasts, e.g., cells derived from 12-16 day old murine fetuses. Methods for the isolation of fibroblasts are well known in the art. For example, fibroblasts may be collected by aseptic removal of the head, liver, heart and alimentary tract from suitable murine fetuses, which are then minced and incubated under suitable conditions to provide for cell dissociation, e.g., incubation with a trypsin containing composition, and the dissociated fibroblasts then plated onto tissue culture dishes containing suitable culture medium.

Any medium suitable for maintaining the cultured feeder cells, e.g., murine fibroblasts, may be used. In partic-

-17-

ular, the present inventors chose to plate fibroblast cells on tissue culture dishes and culture in alpha-MEM medium (BioWhittaker, Walkersville, MD) supplemented with 10% fetal calf serum (FCS) (Hyclone, Logen, UT), penicillin (100
5 IU/ml) and streptomycin (50 µg/ml). However, it is expected that other media may be substituted therefore, including, e.g., DMEM supplemented with glutamine, glucose, 2-mercapto, ethanol, MEM non-essential amino acids, 5-20% serum, anti-
bodies, nucleosides, glutamine (See Strojek et al, Therio-
10 genology 33:981 (1990); Notarianni et al., J. Reprod. Fert. 43 (Suppl): 255 (1990)); and CM beta and BRL conditioned medium (See Handyside et al, Roux's Arch. Dev. Biol., 196:185 (1987)).

After the fibroblasts are cultured to confluence, they
15 are then passaged onto other tissue culture dishes or used directly for culturing of ICM cells and cell lines. Preferably, at some time after passage, and prior to introduction of a ICM, the feeder cells, e.g., fibroblasts, are also
treated with an amount of an antibiotic, e.g., mytomyacin C,
20 preferably from 5 to 100 µg/ml, and more preferably about 10 µg/ml of mytomyacin C, contained in a suitable culture medium, e.g., alpha-MEM or exposed to irradiation to stop or
impede the growth of fibroblasts.

The feeder cells, e.g., fibroblasts are preferably
25 cultured under conditions which allow for the production of a thick confluent monolayer of cells on the culture dishes. For example, this may be effected by maintaining the fibroblasts in a humidified atmosphere, e.g., one containing 5% CO₂ in air at 37°C. However, it is expected that the spe-
30 cific culturing conditions may be varied dependent upon factors including, e.g., the type of feeder cells, age, species, among other factors.

As discussed, culture plates which contain the desired feeder layer, preferably in the form of a thick confluent
35 cell monolayer, are then used to obtain and culture the subject CICM cells and cell lines. This will preferably

-18-

comprise plating the partially separated or intact ungulate ICMs containing at least a portion of the trophectoderm directly onto the mytomycin C treated confluent feeder layer. This is effected by any means which provides for direct physical contact between the cultured ICM and the feeder cells. This may be accomplished by different methods. For example, this may be effected by use of a glass pipette to initiate contact between the ICM and the fibroblast feeder layer. Alternatively, physical contact between feeder cell layer and cultured ICMs may be effected by placing the ICM cells under the feeder layer and the bottom of the culture dish, or by centrifuging ICM cells so as to force them onto the feeder cell layer.

The ICMs are cultured on the feeder layer using any culture medium which allows for the growth and maintenance of ICMs and the desired multilayer colony morphology. Preferably, the C1CM cells or cell lines will be maintained in a growth medium consisting of alpha-MEM supplemented with FCS and 0.1 mM beta-mercaptoethanol (Sigma). However, other culture medium may be substituted therefore including, e.g., the cultured media disclosed supra.

The growth medium is exchanged for fresh medium as necessary during culturing so as to optimize cell growth. This is typically effected about every 2-3 days. However, this may vary dependent upon the specific feeder cells and the selected culture medium. After culturing is effected for several days, usually about 4 days, the first cultured ICM or C1CM colonies will be observed, and some time thereafter, typically at least about 1 day later, the cultured ICMs may then be passaged onto other fibroblast feeder layer containing culture plates.

It has also been found that the passaging efficiency of C1CM cells is enhanced when they are passaged together with some associated feeder cells onto a new feeder layer. Therefore, the new passage contains some of the feeder cells from the previous passage. In passaging the C1CM cells

-19-

together with some associated feeder cells (fibroblasts), it has been found that the passaging efficiency (percentage of CICM cell clumps which result in new colonies) is significantly enhanced.

5 As discussed above, an important part of the invention comprises the discovery that CICM cells comprising a particular combination of morphological properties are preferred for passaging and the production of cultured ICM cells and cell lines having the desired properties. Specifically,
10 cells which possess the following morphological characteristics are preferred:

(i) small cytoplasmic/nuclear volume ratio (ranging from about 10/90 to about 50/50, more preferably about 10/90 to about 30/70, and most preferably about 25/75);

15 (ii) observable cytoplasmic vesicles; and

(iii) small individual cells, ranging from about 10 - 20 μ m in diameter, and preferably less than about 15 μ m in diameter.

Calculation of cytoplasmic/nuclear volume ratios may be
20 easily determined by observing cultured cells under the microscope, taking appropriate measurements, and making appropriate volumetric calculations. Similarly, cytoplasmic vesicles can easily be observed in cultured cells. Finally, cell size can be easily determined by measuring cell diameters of CICMs comprised on the feeder layer culture.
25

It has been surprisingly discovered by the present inventors that these morphological properties are important for the isolation and propagation of cultured ICM cells and the production of cell lines having the desired morphological and cell marker characteristics and which maintain such
30 properties for prolonged periods in tissue culture, i.e., after repeated passaging.

More specifically, the present invention was based on the observation that when ICM or passaged CICM cell lines
35 initially attach to the feeder layer, multiple layer colonies shortly become visible, typically after about 2 days.

-20-

However, these multilayer colonies generally begin to flatten into epithelial sheets of cells as the cells propagate in vitro. Related to this observation, it was discovered that while the cells contained in the multilayer section of the colony are AP positive and cytokeratin 18 negative, the flattened epithelial-like cells are AP negative and cytokeratin 18 positive. Thus, the epithelial-like cells express cell markers differently from ICMs of developing fetuses. Accordingly, it was discovered that ICMs cultured on feeder cell layers over time gradually exhibit a morphology and express cell markers which are inconsistent with ICMs of undifferentiated developing embryos. This is undesirable because CICMs which exhibit properties identically or substantially similarly to undifferentiated ICMs of developing embryos will potentially be totipotent and therefore should be useful in chimeric and nuclear transfer (NT) techniques.

Thus, the goal of the present invention was to develop culturing methods which maintain or revert these ICM cell colonies such that they comprise the desired multilayered colony morphology. It was theorized, based on the described morphology of the ICM colony, that specific cells could be separated and used for passaging and that these separated cells might potentially result in the production of cultured ICMs having the desired multilayer morphology.

As noted, it was observed that the growing ICM cell colony, while initially entirely multilayer, quite rapidly flattens out to produce an epithelial sheet of cells having two distinct populations of cells within the colony. The first population is comprised on the outer perimeter of the cell colony and possesses a multilayer structure and includes cells which possess the following morphological characteristics:

- (i) small cell size (cells ranging from about 10 - 20 μm in diameter, preferably less than 15 μm in diameter);
- (ii) observable cytoplasmic vesicles; and

-21-

(iii) small cytoplasmic/nuclear volume ratio (ranges from about 10/90 to about 50/50, preferably about 10/90 to about 30/70, and most preferably about 25/75.)

5 This outer section of the colony was also found to stain strongly positive for AP activity. By contrast, the cells in the middle of the colony tend to be comprised of flattened epithelial-like cells which exhibit little or no AP activity.

10 Based on the observed AP activity and multilayer structure, the present inventors decided to selectively passage only or substantially only the cells in the outer perimeter of the cell colony and specifically the cells having small cytoplasmic volume/nuclear volume ratio, observable cytoplasm vesicles and small cell size (defined supra) in the hope that these cultured cells would produce additional multilayer CICM cell colonies having the desired morphology. However, this outcome was not at all assured. To the contrary, it was possible that such passaging could have instead resulted in colonies consisting entirely of flattened epithelial-like cells, particularly if the observed epithelial-like appearance and altered cell marker expression were a consequence of culturing ICMs in vitro over prolonged time or a consequence of ICM cell passaging.

25 Quite surprisingly, the present inventors discovered that the selective passaging of cells comprised in the perimeter of the multilayer cell colony, possessing the above-enumerated morphological characteristics produced ICM multilayer colonies. Also, it was surprisingly found that these multilayer colonies contain cells which express cell markers identically or substantially similarly to ICM of developing embryos. Moreover, it was found that the subject method provides for the maintained production of CICMs which exhibit a morphology and express cell markers identically or substantially similarly to ICM of developing ungulate embryos, theoretically indefinitely. CICMs produced according to 35 the invention maintain such properties for prolonged periods

-22-

in culture, i.e., for at least one passage, after about 5 to 10 passages, and more preferably after about 10 to 50 passages.

5 The selective passaging of cells having the desired morphological characteristics may be accomplished by known cell separation methods. For example, the multilayered portion of the colony which constitutes the perimeter of the colony may be separated from the middle portion of the colony by physical means, e.g., using a glass pipette or a
10 needle. The large cell clumps which result can then be further broken down by physical and/or chemical and/or enzymatic means. For example, cell dissociation may be effected by the use of enzymes, e.g., trypsin or pronase. Alternatively, mechanical cell separation may be effected by
15 repeatedly pipetting large cell clusters or cell clumps through a cell pipette or by use of a needle or razor blade to cut large cell clumps into smaller groups. Preferably, such chemical and/or mechanical cell separation will produce CICM clusters suitable for passaging, i.e., which contain
20 about 5 to 100 cells.

The separated cells used for passaging will preferably consist of cells contained in the multilayer peripheral section of the cell colony, preferably having the above-recited morphological characteristics. However, in some
25 cases, even cells from the inner portion of the cell colony, when treated according to the invention, are found to produce multilayer colonies after passaging onto a new feeder layer.

This is believed to occur because the cells revert back
30 to the desired multilayer colonies either because of the passaging procedure or the reestablishment of cell-to-cell contact with the new feeder layer. However, the present inventors do not wish to be bound by their belief.

During passaging, it is essential that the small ICM
35 cells or cell clusters be placed into direct contact with the feeder layer to prevent CICM colony differentiation. It

-23-

has been found that if the cells or cell clusters are grown without sufficient contact with feeder layers that this instead results in embryoid bodies. Such embryoid bodies may be observed in Figure 1 which is a photograph showing
5 cultured ICM cells grown without sufficient contact with a feeder layer.

To initiate direct contact, any method may be used which provides for direct cell contact between passaged CICM cells and feeder cell layer which is not degradative to the
10 CICMs and does not adversely affect colony production. The least efficient means is to simply allow the small clumps of cells to settle down on top of the feeder layer. It is more preferable to use methods which provide for more efficient cell-to-cell contact between the CICM cells and the feeder
15 layer. This has been found to result in a higher number of multilayer CICM cell colonies.

Any physical means which provides for enhanced physical contact between the CICM cells and the feeder cells, but which is not unduly degradative, i.e., does not adversely
20 affect the production of the desired multilayer type cells and CICM cell lines may be used. Methods for providing for increased direct contact of passaged CICMs and the feeder layer include, by way of example, the use of a pipette to press the individual clumps of cells onto the feeder layer;
25 the placement of CICM cell clusters under the feeder layer so that the cells are sandwiched between the feeder layer and the bottom of the dish; and the centrifugation of clumps of cells on top of the feeder layer, e.g., from between 100 and 5000 g for about 10 minutes to 5 hours to force the cell
30 clusters onto the feeder layer. These methods are merely exemplary of methods which may be used to force the CICM cell clusters into close contact with the feeder layer. Other methods may be substituted therefore provided that they do not adversely affect the formation of the desired
35 multilayer CICM cell colonies. As discussed above, it has also been found that passaging efficiency may further be

-24-

enhanced by passaging CICM cells together with some associated feeder cells onto the new feeder colony. Apparently the presence of some of the feeder cells from the previous passage enhances the percentage of CICM cell clumps which
5 result in new colonies.

In general, the above culturing procedure for culturing CICM cells is applicable to any ungulate derived CICM cells. For example, procedures initially found to be suitable for culturing pig CICM cells have been found to be applicable to
10 bovine CICM cells. However, one observed difference is that the majority of cells derived from bovine embryos are AP negative whereas those derived from pig embryos are AP positive. It is hypothesized that there may exist species differences in AP expression in cows and pig ICMS. However,
15 this is unclear because the inventors were able to produce one bovine cell line that was weakly AP positive and which grows in small clumps. (See Figure 2).

Also, the bovine cells differ from the pig cells in that the borders of the colony are not as well defined.
20 However, similar to the pig derived cells, the cells comprised in the perimeter of the colony are AP positive whereas cells in the center of the colony tend to lose AP activity. This also may be appreciated upon review of Fig. 2. Similar to pig derived CICMs, these cells are cytokeratin 18
25 negative.

As shown in the Examples, and described in more detail infra, the subject CICMs are useful for the introduction of heterologous DNAs. In particular, transgenic CICM cell lines have been produced which contain within their genome a
30 heterologous DNA (beta-galactosidase DNA construct). Also, recently the inventors obtained cells using the above-described culturing methods which were somewhat different from the described CICM cells in their morphology, ability to differentiate, level of endogenous beta-galactosidase activity (higher), and ability to express beta-galactosidase DNA
35 constructs. Moreover, these cells were AP negative from the

-25-

onset of culturing, whereas previous CICM cells of pigs tended to lose AP activity over time during culturing. Similar cells have been observed and propagated in CICMs derived from cows. Although these cells lack AP activity, they exhibit some characteristics in common with ICM cells. Therefore, they may also be useful for production of transgenic cloned embryos, as well as the other described applications of CICMs.

The present invention further provides another method for providing cultured ICM cells and cell lines having the desired morphological and cell marker characteristics, e.g., CICMs which are AP positive and cytokeratin 18 negative. This second method will also involve obtaining and culturing ICMs, preferably from blastocyst or preblastocyst stage embryos of ungulates on feeder cell layer cultures. Preferably, the culturing techniques and passaging methods will be effected as described above.

However, the second method differs in the fact that the cultured ICM cells will express, preferably only under specific conditions, a differentiation inhibiting (DI) gene. This is preferably accomplished by introducing into the ICM cells, at some time during the culturing or passaging procedures, a nucleic acid sequence which includes a differentiation inhibiting gene, which is preferably expressed under the control of an inducible or regulatable promoter.

As noted above, DI genes refer to any gene or genes which may inhibit cell differentiation in the CICM cell colonies which do not adversely affect the isolation of CICM cell lines having the desired morphological characteristics and cell marker expression. The DI gene, preferably operably linked in proper reading frame to a regulatable or inducible promoter may be introduced into the nucleus of embryonic cells from which the CICM cell lines are derived during passaging, or alternatively introduced into an established CICM cell line.

-26-

This is effected in a manner which results in the DI gene, or transgene as it may be accurately described, being integrated into the genome of the embryonic ICM or cultured ICM cells or cell line. Methods for introducing desired
5 DNAs into mammalian cells and embryonic cells in particular are known in the art and include by way of example microinjection, electroporation, lipofection, retroviral insertion, Ca precipitation, and liposome insertion. To date, microinjection appears to be the most efficient means for intro-
10 ducing the DNA into C127 cell lines. However, it is expected that other methods will also be effective with appropriate optimization.

Differentiation inhibiting genes suitable for use in the invention include, e.g., tsA58 (See WO 91/13150), other
15 T antigens and oncogene products known to inhibit differentiation (See WO 91/13150 for examples thereof), OCT3 (Okamoto et al., Cell, 60:461 (1990), Rosner et al., Nature, 345:686, (1990), LIF and the LIF receptor (Smith et. al., Nature, 336:688 (1988)). These DI genes are merely exem-
20 plary of those which may be used in the present invention.

The DI gene is preferably placed under the control of an inducible or regulatable promoter. As noted, examples of inducible promoters are well known in the art and include by way of example the metallothionein promoter (metal ion
25 inducible), as well as the response elements for tetracycline, interferon and steroid (See WO 94/29442; Kimura et al., Cell, 44:261 (1986); Yarranton, Curr. Opin. Biotech, 3:506 (1992)).

After the transgene is integrated into the embryonic or
30 cultured ICM cells or cell line, and the resultant transgenic cells are established onto feeder cell cultures, the DI gene or genes are turned on by inducing the particular inducible promoter. This is typically effected by adjustment of culturing conditions. For example, if the promoter
35 is the metallothionein promoter induction is effected by introduction of a culture medium containing appropriate

-27-

metal ions which induce ("turn on") the promoter. Thereby, when the cells are cultured under induction conditions, the cultured ICM cells should continually or for prolonged periods in tissue culture maintain the desired CICM cell morphology and gene expression characteristics. More specifically, the cells should exhibit the desired multilayer cell colony morphology and express cell markers identically or substantially similarly to ICMs of developing embryos, i.e., the cells will generally be AP positive and cytokeratin (cytokeratin 18) negative. Thereby, problems such as ICM cell colonies differentiating into flattened epithelial sheets which are AP negative and cytokeratin 18 positive (which are observed when ICMs are cultured under conventional conditions) should be minimized or even eliminated. Moreover, this should also prevent the differentiation of ICM cells during passage and during sustained culture periods.

The resultant cultured ICM cells and cell lines which are obtained by the above-described methods possess numerous usages. Most especially, these CICM cell lines may be used to produce offspring which possess the CICM genetic makeup in whole or part.

Chimeric offspring may be obtained by injecting the CICM cells directly into the blastocoele cavity of recipient embryos or combined with pre-blastocyst stage embryos. The resultant chimeric embryos are then placed into a recipient female. The resultant offspring should then have a CICM genetic contribution to all organ systems including the germ cells of the reproductive organ. Thereby, the chimeric animal can pass the CICM genetics into subsequent generations of offspring. Also, the introduced CICM may have introduced in their genome a desired gene or genes. Thereby, chimeric offspring may be obtained which express a desired gene or genes. For example, genes may be introduced into CICMs which provide for enhanced livestock properties, e.g., which encode hormones, which provide for disease

-28-

resistance, (e.g., lymphokines, viral resistance genes, bacterial resistance genes), enhanced milk production, altered fat percentages, enhanced body weight, among other enhanced properties. Also, genes may be introduced which
5 encode for desired gene products, e.g., genes which encode products useful as human therapeutics or for xenotransplantation.

Also, the subject C1CM cells may be used in nuclear transfer procedures to obtain nuclear transfer embryos,
10 fetuses and offspring. Nuclear transfer techniques are known in the literature and are described in many of the references discussed in the Background of the Invention. See in particular, Campbell et al., Theriogenology, 43:181 (1995); Collas et al., Mol. Reprod. Dev., 38:264-267 (1994);
15 Keefer et al., Biol. Reprod., 50:935-939 (1994); Sims et al., Proc. Natl. Acad. Sci. USA, 91:6143 (1994); Stice et al., Theriogenology, 41:301 (1994); Sims et al., Proc. Natl. Acad. Sci. USA, 90:6143-6147 (1993); WO 94/26884; WO 94/24274; and WO 90/03432 which are incorporated by
20 reference in their entirety herein. Again, if the C1CM contributes to fetal germ cells, the C1CM genetics can be passed onto subsequent generations of animals. Similarly, the C1CM cells may be genetically engineered such that they have integrated into their genome a desired gene or genes,
25 e.g., genes which provide for enhanced livestock properties, or which encode for desired gene products, e.g., human therapeutics or other polypeptides.

Still further, differentiated cells, tissues or organs produced by nuclear transfer or obtained from chimeric
30 fetuses or offspring may be used in transplantation therapies. For example, nuclear transfer or chimeric fetuses derived from C1CM cells containing an anti-rejection gene or genes may provide a source of hematopoietic cells useful to supplement or replace human hematopoietic stem cells. This
35 is potentially useful in immunocompromised patients, e.g., AIDS patients or other diseases affecting hematopoietic stem

-29-

cells. Also, stem cells may be useful in treatment of Huntington's disease, Parkinson's disease and Alzheimer's disease. Moreover, pancreatic cells may be useful in diabetes treatments. Further transplanted liver cells may
5 be useful for the treatment of liver diseases. Alternatively, whole soft organs may potentially be transplanted from genetically altered CICM-derived ungulates into humans (See Durling et al., Curr. Omp. Immunol., 6:765 (1994)) incorporated by reference in its entirety herein.

10 Also, the subject CICM cell lines may be used as an in vitro model of differentiation, in particular for the study of genes which are involved in the regulation of early development.

This is only exemplary of potential applications of
15 CICM cell lines obtained according to the present invention.

The invention will now be described in more detail in the following Examples.

EXAMPLE 1

20 Production of CICM cell lines from pre-blastocyst and blastocyst stage pig embryos were conducted using the following general protocol. First, primary cultures of embryonic fibroblasts were obtained from 12-16 day old murine fetuses. After the head, liver, heart and alimentary tract
25 were aseptically removed, the embryos were minced and incubated for 30 minutes at 37°C in prewarmed trypsin EDTA solution (p.05% trypsin/0.02% EDTA; GIBCO, Grand Island, NY). Fibroblast cells were plated in tissue culture dishes and cultured in alpha-MEM medium (BioWhittaker, Walkersville, MD) supplemented with 10% fetal calf serum (FCS)
30 (Hyclone, Logen, UT) penicillin (100 IU/ml) and streptomycin (50 µg/ml). Three to four days after passage, embryonic fibroblasts, in 35 x 10 Nunc culture dishes (Baxter Scientific, McGaw Park, IL), were treated with mitomycin C
35 (10µg/ml; Sigma) in supplemented alpha MEM for a minimum of three hrs. The fibroblasts were grown and maintained in a

-30-

humidified atmosphere with 5% CO₂ in air at 37°C. Only culture plates which had a thick confluent monolayer of cells were used to culture the CICM cell lines. The characteristics of the feeder layer is an important factor in obtaining and propagating undifferentiated CICM cell lines.

Porcine embryos were surgically collected from the reproductive tract post mortem or during surgical laparotomy. The ICM of blastocyst stage embryos were either partially separated from the trophoblast cells using a cutting needle, incubated in trypsin or pronase, or left intact. The ICM and at least a portion of the trophectoderm was plated directly onto the mitomycin C blocked fibroblast cells often using a glass pipette to initiate contact between the ICM and the fibroblast feeder layer. The CICM cell lines were maintained in a growth medium consisting of alpha MEM supplemented with 10% FCS and 0.1 mM beta-mercaptoethanol (Sigma). Growth medium was exchanged every two to three days. Initial colonies were observed by the fourth day of culture and could be passaged any time after the fifth day. Only cells having the following three morphological features were isolated for passage: a small cytoplasmic/nuclear volume ratio, cytoplasmic vesicles, and generally small individual cells (less than 15 µm in diameter). These cells are often isolated from multilayer portions of the colony which maintained direct contact with the feeder layer. The portions of the colony that met this criteria were often AP positive and cytokeratin negative upon passage onto a new feeder layer.

When the ICM or the passaged CICM cells initially attach to the feeder layer, multiple layer colonies consisting of small cells are visible after two days in culture. This can be seen in Fig. 3. The multilayer colonies are AP positive and cytokeratin negative (See Figs. 4 and 5). However, some of the colonies begin to form an epithelial-like sheet of cells. The epithelial-like cells are AP negative and cytokeratin positive (Figs. 6 and 7). In

-31-

addition, the multilayer colonies often begin to flatten into epithelial sheets of cells as they propagate *in vitro* (Fig. 8).

It was observed by the inventors that a growing multi-
5 layer colony begins to flatten out, forming an epithelial sheet of cells having two distinct populations of cells within the colony. The first population resides in an area around the perimeter of the colony. This section of colony is multilayered and the individual cells are small and
10 possess cytoplasmic vesicles (Fig. 8). This area also stains positive for AP activity. The other area of the colony contains the flattened epithelial-like population of cells. These cells tend to be in the middle of the colony. In this population of cells, individual cells and cell
15 borders can be observed when viewing the colony under a microscope (Fig. 8). Again, these cells have very little AP activity or none at all.

It was theorized that to maintain the desired multi-layer type cells, preferably, only the cells around the
20 perimeter would be selectively passaged to produce additional multilayer colonies.

This is probably accomplished by using a glass pipette razor or a needle to cut out the multilayer portions of the colony (perimeter cells). The large groups of cells can be
25 broken down further either by mechanical separation or by using trypsin (0.05% trypsin/0.2% EDTA) along with the mechanical separation. Mechanical separation is conducted by repeatedly pipetting large clumps of cells up and down through a small bore pipette. Alternatively, a needle or
30 razor blade can be used to cut the large group of cells into smaller groups. It was surprisingly found that CICM clumps obtained by all these methods (5 to 100 cell) can then be passaged onto new feeder layers to produce cultures having the desired multilayer morphology. In some occasions even
35 cells from the inner portion of the colony when treated in this same manner, produced multilayer colonies after passage

-32-

onto new feeder layers. It is hypothesized that these cells reverted back to the multilayer colonies as a result of either the passage procedure or the reestablishment of cell to cell contact with the new feeder layer.

5 It was observed that the small clumps of cells must be placed back in direct contact with the feeder layer to prevent CICM colony differentiation. By contrast, cells grown without contact with feeder layers form embryoid
10 bodies (Fig. 1). There are several methods used to re-initiate feeder layer contact. The least efficient means is to allow the small clumps of cells to settle down on top of the feeder layer after the cell culture plates are placed back in the incubator. A preferred method involves forcing
15 cell to cell contact between the CICM cells and the feeder layer. This results in a higher number of newly established CICM cell colonies. One way to force cell to cell contact is to use a pipette to press the individual clumps of cells down on top of the feeder layer. Another method is to place
20 the clump of CICM cells under the feeder layer so that the cells are forced between the feeder layer and the bottom of the culture dish. Still alternatively, clumps of cells on top of the feeder layer can be centrifuged between (100 and 5000 g) for (10 min to 5 hrs) to force the cells down on top
25 of the feeder layer. Essentially, any method which forces the passaged clumps of CICM cells into close contact with the feeder layer results in the production of CICM cell colonies having the desired multilayer morphology. Also, as
discussed previously, passaging efficiency may be further enhanced by passaging CICM cells along with some associated
30 feeder cells onto the new feeder layer.

EXAMPLE 2

CICM cells obtained according to Example 1 were used for insertion of heterologous DNA's. Specifically, these
35 cells were microinjected with linear as well as supercoiled DNA constructs containing different promoters placed in

-33-

front of either the beta-galactosidase gene and/or the neomycin phosphotransferase gene. The specific promoters used were the cytomegalovirus promoter (CMV promoter), phosphoglycerate Kinase promoter (PGK promoter), mammary promoter (MAM promoter), reCMV promoter and chicken beta actin promoter. These gene constructs were diluted in a buffered solution (containing 80mM KCl and 70mM HEPES.) However, other buffers may readily be substituted therefore, such as Tris EDTA. The concentration of the DNA constructs in solution ranged from 5 to 10 μ g/ml. However, concentrations ranging from 0.1 to 100 μ g/ml should be effective. These DNA preparations were then microinjected into cultured CICM cells obtained according to Example 1.

In this procedure, the individual CICM cells within the colonies were located by viewing the colonies through an inverted microscope. Thereafter, the cell membrane alone or additionally the nuclear membrane was punctured using a small injection needle containing the DNA preparation. The opening in the needle was about 1 μ m. Such a diameter needle was selected to help prevent CICM cell lysis. Moreover, the microinjection procedure was facilitated by the use of a micromanipulator which was attached to the inverted microscope.

After the injection pipette was introduced into the nucleus, approximately 700 copies of the DNA were released into the nucleus. The micropipette was then removed from the cell. This process was repeated for other cells in the CICM colony. Ideally, 1000 cells may be microinjected per hour.

The results obtained using the different promoters are summarized in the following table.

Heterologous Gene Expression in Microinjected CICM Cells

promoter	expression two hours after injection	expression five days after injection
CMV	+++	++

-34-

PGK	++	none
reCMV	++	not tested
MAM	++	not tested
C-Actin	+	not tested

5

The above results demonstrate that vectors containing each of the tested promoters result in cells which express the inserted heterologous DNA. It was also observed that microinjection with several constructs did not provide for any additive effects on gene expression.

Figure 9 is a photograph of microinjected pig C1CM cells containing a CMV beta-galactosidase construct detected by X-gal staining. Nests of cells expressing b-galactosidase may be seen. This indicates that the β -galactosidase gene has been effectively incorporated into the cell genome and is being transmitted and expressed in daughter cells.

The above results were obtaining using pig C1CM cells. Moreover, using similar methods, bovine C1CM cells were also injected with CMV and PGK-beta-galactosidase constructs. Both DNA constructs resulted in recovery of cells which express beta-galactosidase.

Thus, these results demonstrate that C1CM's cultured according to the invention may successfully be used for integration and expression of desired heterologous DNA's. Also, these gene expression characteristics may be passed onto daughter cells.

EXAMPLE 3

In this culturing method, a DI gene is conditionally expressed in C1CM cell colonies to prevent cell differentiation. The cell passage and culture techniques are the same as in Example 1 with the difference being the genetic makeup of the C1CM cells. Specifically, a DI gene is introduced into the nucleus of embryonic cells from which the C1CM cell lines are derived or into an established C1CM cell line.

-35-

The transgene is then integrated into the genome of the C1CM cells. Any known methods of introducing transgenes into embryonic cells can be used, including by way of example microinjection, electroporation, retroviral insertion, Ca precipitation, and liposome insertion.

The inserted transgene is expressed under the control of an inducible promoter. Inducible promoters include, e.g., response elements such as tetracycline (WO 94/29442), interferon (Kimura et al., 1986), steroid and metallothionein (reviewed by Yarranton, 1992). Accordingly, the DI gene is inserted such that it is operably linked, in proper reading frame, with an inducible promoter.

After the chimeric gene construct is integrated into the genome of the embryonic cells and the multilayer ICM cell colony is established, the DI gene is expressed by inducing the inducible promoter. This expression provides for the ICM cell colony to continuously, or for prolonged time in tissue culture, maintain the desired multilayer morphology and to express genes consistent with ICM of developing embryos. Thus, problems such as cells differentiating into flattened epithelial sheets that lose their AP expression and express cytokeratin 18 are minimized or even avoided altogether. This method is also useful in preventing differentiation of cells during long term culture periods.

While the invention has been described with respect to certain specific embodiments, it will be appreciated that many modifications and changes thereof may be made by those skilled in the art without departing from the spirit of the invention. It is intended, therefore, by the appended claims to cover all modifications and changes that fall within the true spirit and scope of the invention.

-36-

WHAT IS CLAIMED IS:

1. A method for producing a cultured inner cell mass (CICM) cell which comprises the following steps:
 - 5 (i) obtaining an ICM of a blastocyst or ICM progenitor cells from preblastocyst stage embryo;
 - (ii) culturing said ICMs or ICM progenitor cells on a feeder layer culture under conditions which provide for the formation of multilayer cell colonies;
 - 10 (iii) identifying from among the cells contained in the cultured ICM cell colony those cells which exhibit the following properties:
 - (a) small cytoplasmic/nuclear volume ratio;
 - (b) cytoplasmic vesicles;
 - 15 (c) small individual cells relative to rest of the cell colony;
 - (iv) separating one or a cluster of said identified cells from the rest of the cell colony; and
 - (v) passaging said separated ICM cells or ICM progenitor cells onto another feeder layer culture under conditions whereby there is at least some physical contact between the feeder cell layer and the separated cells or cell cluster.
- 25 2. The method of claim 1 wherein said ICM obtained in step (i) include at least a portion of the trophectoderm.
3. The method of claim 1 when the feeder cell layer comprises fibroblasts.
- 30 4. The method of claim 3 wherein said fibroblasts are murine embryonic fibroblasts.
5. The method of claim 4 wherein said murine embryonic fibroblasts are primary cells.
- 35

-37-

6. The method of claim 3 wherein said fibroblasts comprise a thick confluent monolayer.

7. The method of claim 1 wherein the method for producing
5 for physical contact of the separated cultured ICM cells and the feeder cell layer is selected from the group consisting of (i) placing the separated ICM cells on top of the feeder cell layer, (ii) pressing C1CM cell clusters onto the feeder layer, (iii) placing C1CM cell clusters between the feeder
10 cell layer and the culture dish, and (iv) centrifuging the C1CM cells or cell cluster onto the feeder cell layer.

8. The method of claim 1 wherein the separated identified cells are comprised in the outer portion of the multilayer
15 C1CM cell colony.

9. The method of claim 8 wherein the separated cells further include some cells comprised in the inner epithelial-like portion of the cell colony.
20

10. The method of claim 1 wherein the identified cells are separated from the colony by at least one of the following: physical or chemical or enzymatic means.

25 11. The method of claim 10 wherein said physical means comprises the use of a glass pipette, hypodermic needle or razorblade.

12. The method of claim 11 which further comprises treatment of separated cells with trypsin or pronase.
30

13. The method of claim 1 wherein the separated cells comprise a cluster of about 5 to 100 cells.

35 14. The method of claim 1 wherein steps (ii) through (v) are repeated.

-38-

15. The method of claim 1 wherein the cytoplasmic/nuclear ratio ranges from about 10/90 to about 50/50.
16. The method of claim 15 wherein said ratio is about 25
5 to 75.
17. The method of claim 1 wherein the cells range in size from about 10 to 20 microns in diameter.
- 10 18. The method of claim 2 wherein the cells are less than about 15 microns in diameter.
- 15 19. Cultured inner cell mass cells (CICM cells) derived from the ICM of a blastocyst or derived from ICM progenitor cells obtained from preblastocyst ungulate embryo wherein said cultured inner cell mass maintain in culture the morphological characteristics and express cell markers identically or substantially similarly to ICMS of developing ungulate embryos.
- 20 20. The CICMs of claim 19 which express alkaline phosphatase.
- 25 21. The CICMs of claim 19 which do not express cytokeratin 18.
22. The CICMs of claim 19 wherein said cells exhibit a multilayer colony morphology in tissue culture.
- 30 23. The CICMs of claim 21 wherein said multilayer colony morphology comprises an inner epithelial-type portion and a multilayer portion which substantially surrounds said epithelial-like portion.

-39-

24. The CICMs of claim 19 wherein the ungulate embryo is obtained from an ungulate selected from the group consisting of pigs, cows, sheep, horses and goats.

5 25. The CICMs of claim 24 wherein the ungulate is a pig.

26. The CICMs of claim 24 wherein the ungulate is a cow.

27. A cultured inner cell mass cell line obtained from the
10 CICMs of claim 19.

28. The CICMs of claim 19 which comprise one or more genes which inhibit differentiation of said CICMs.

15 29. The CICMs of claim 28 wherein said gene is selected from the group consisting of tsA58, OCT3, LIF, LIF receptor, FGF-5, REX-1 and other oncogene products, T antigens, cytokines and transcription factors.

20 30. The CICMs of claim 10 which comprise integrated within their genome a heterologous DNA.

31. The CICMs of claim 30 wherein the heterologous DNA encodes for a selectable marker.

25

32. The CICMs of claim 30 wherein the heterologous DNA encodes for a desired polypeptide.

33. A method for obtaining cultured inner cell mass cells
30 which exhibit morphological characteristics and which express cellular markers consistent with or substantially similarly to that of ICMs of differentiating ungulate embryos for prolonged periods in tissue culture which comprises:

35 (i) obtaining ungulate ICM cells or an established cultured ungulate ICM cell line;

-40-

(ii) introducing into the nucleus of said ICM cells or established cultured ICM cell one or more genes which inhibit differentiation of said ICM cells or cell line (DI genes);

5 (iii) culturing the resultant transgenic ungulate ICM cells or cell line on a suitable feeder cell culture under conditions which inhibit differentiation and provide for the production of a multilayer cell colony.

10 34. The method of claim 33 wherein said DI genes are selected from the group consisting of tsA58, OCT3, LIF, LIF receptor and other oncogene products or T antigens.

15 35. The method of claim 33 wherein said DI gene is expressed under the control of an inducible promoter and the culturing conditions comprise those which induce said promoter.

20 36. The method of claim 33 wherein said cells are passaged.

37. The method of claim 36 wherein said passaging method comprises:

(i) culturing said ICMs on a feeder layer culture under conditions which provide for multilayer cell colonies;

25 (ii) identifying from among the cultured ICM cell colony those cells which exhibit the following properties:

(a) small cytoplasmic/nuclear volume ratio;

(b) cytoplasmic vesicles;

30 (c) small individual cells relative to rest of the cell colony;

(iii) separating one or a cluster of said identified ICM cells from the rest of the cell colony by suitable means; and

35 (iv) passaging said separated cultured ICM cells onto another feeder layer culture under conditions whereby there

-41-

is at least some physical contact between the feeder cell layer and the separated cells or cell cluster.

38. The method of Claim 33, wherein in step (iv) the separated passaged ICM cells include some associated feeder cells.

39. The method of claim 33 wherein the ungulate embryo is obtained from an ungulate selected from the group consisting of pigs, cows, sheep, goats and horses.

40. The method of claim 39 wherein the ungulate is a pig.

41. The method of claim 39 wherein the ungulate is a cow.

1/5



Fig. 1




Fig. 2

2/5



Fig. 3




Fig. 4

3/5



Fig. 5



Fig. 6

4/5




Fig. 7




Fig. 8

5/5



Fig. 9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04736

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : C12N 15/00, 5/00 US CL : 435/172.3, 69.1, 325; 800/2 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/172.3, 69.1, 325; 800/2 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, EMBASE, BIOSIS, CAPLUS, WPIDS, APS																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X --- Y	FIRST et al. Systems for Production of Calves from Cultured Bovine Embryonic Cells. Reproduction, Fertility, and Development. 1994, Vol. 6, pages 553-562, see entire document.	1-9 ----- 10-41																		
Y	BARTLETT et al. Evaluation of extracellular matrices and the plasminogen activator system in sheep inner cell mass and trophectodermal outgrowth in vitro. Biology of Reproduction. 1995, Vol. 52, pages 1436-1445, see entire document.	1-41																		
X --- Y	TALBOT et al. In vitro pluripotency of epiblasts derived from bovine blastocysts. Molecular Reproduction and Development. 1995, Vol. 42, pages 35-52, see entire document.	1-9 ----- 11-41																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 23 MAY 1997		Date of mailing of the international search report 24 JUN 1997																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer JILL SCHMUCK																		
Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196																		

INTERNATIONAL SEARCH REPORT

Int. application No.
PCT/US97/04736

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	TALBOT et al. Culturing the epiblast cells of the pig blastocyst. In Vitro Cellular and Development Biology. July 1993, Vol. 29A, pages 543-554, see entire document.	1-9 --- 11-41
X --- Y	ANNELIES et al. Isolation and Characterization of Permanent Cell Lines from Inner Cell Mass Cells of Bovine Blastocysts. Molecular Reproduction and Development. 1995, Vol. 40, pages 444-454, see entire document.	1-9 --- 11-41
Y	COLLAS et al. Nuclear Transplantation by Microinjection of Inner Cell Mass and Granulosa Cell Nuclei. Molecular Reproduction and Development. 1994, Vol. 38, pages 264-267, see entire document.	1-41
Y	SIMS et al. Production of calves by transfer of nuclei from cultured inner cell mass cells. Proceedings of the National Academy of Sciences, USA. June 1993, Vol. 90, pages 6143-6147, see entire document.	1-41